Kjar Richard A, Powell Gerard J, Schilcht Stephen M, Smith Peter J, Slavin John, Choong Peter F M
St Vincent's Hospital, Melbourne, VIC.
Med J Aust. 2006 Jun 5;184(11):563-5. doi: 10.5694/j.1326-5377.2006.tb00381.x.
To review our experience with percutaneous radiofrequency ablation (RFA) for osteoid osteoma.
PARTICIPANTS, DESIGN AND SETTING: Retrospective review of 24 patients with osteoid osteoma treated with percutaneous RFA at St Vincent's Hospital, Melbourne, from August 2000 to February 2005.
Initial response to treatment, return of symptoms, time to recurrence, complications and histopathological correlation.
In 23 of 24 patients, there was immediate relief of symptoms. One-third of patients had a return of symptoms. The 24 patients underwent a total of 32 RFA procedures. Of the eight patients who had a recurrence, five had an initial lesion > or = 10 mm in maximum diameter. Twenty-three of the 24 patients were pain-free at the end of the study period. Patients were followed up for a median of 26 months. There were no long-term complications.
Percutaneous RFA is a safe and efficacious treatment for osteoid osteoma with a low morbidity rate. Despite recurrence after treatment, re-treatment is simple and effective.
回顾我们采用经皮射频消融（RFA）治疗骨样骨瘤的经验。
参与者、设计与背景：对2000年8月至2005年2月在墨尔本圣文森特医院接受经皮RFA治疗的24例骨样骨瘤患者进行回顾性研究。
治疗的初始反应、症状复发情况、复发时间、并发症及组织病理学相关性。
24例患者中有23例症状立即缓解。三分之一的患者症状复发。24例患者共接受了32次RFA治疗。8例复发患者中，5例初始病灶最大直径≥10毫米。24例患者中有23例在研究结束时无痛。患者的中位随访时间为26个月。无长期并发症。
经皮RFA是治疗骨样骨瘤的一种安全有效的方法，发病率低。尽管治疗后会复发，但再次治疗简单有效。
